Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen's stock has taken a hit, dropping over 5% following a disappointing forecast for 2025 adjusted earnings per share (EPS). The company anticipates EPS between $15.25 and $16.25, with the midpoint falling short of the consensus estimate of $16.16. This grim outlook comes amidst broader market challenges, characterized by rising...

Biogen's Stock Plummets Over 5% as 2025 Earnings Forecast Falls Short of Expectations Amidst MS Sales Decline and Market Volatility

Biogen faces a challenging landscape as its stock drops over 5% following a disappointing 2025 earnings forecast, driven by a decline in multiple sclerosis sales and market volatility. With a strategic overhaul underway, can Biogen's new drug launches and restructuring efforts turn the tide?